Exosomal survivin facilitates vesicle internalization.

Oncotarget

Center for Health Disparities Research and Molecular Medicine, Loma Linda University, Loma Linda, California, 92350, USA.

Published: October 2018

Survivin, a member of the inhibitor of apoptosis (IAP) protein family plays a significant role in cell fate and function. It is significantly overexpressed in tumor cells and has been identified in most cancer cell types. A novel extracellular population has recently been identified and its function is still unknown. Emerging evidence continues to shed light on the important role the tumor microenvironment (TME) has on tumor survival and progression. This new population of survivin has been seen to enhance the tumor phenotype when internalized by recipient cells. In this paper, we sought to better understand the mechanism by which survivin is taken up by cancer cells and the possible role it plays in this phenomenon. We isolated the exosomal carriers of extracellular survivin and using a lipophilic stain, PKH67, we tracked their uptake with immunofluorescence and flow cytometry. We found that by blocking exosomal survivin, exosome internalization is reduced, signifying a novel function for this protein. We also discovered that the common membrane receptors, transferrin receptor, endothelin B receptor, insulin receptor alpha, and membrane glucocorticoid receptor all facilitate exosomal internalization. This understanding further clarifies the protein-protein interactions in the TME that may influence tumor progression and identifies additional potential chemotherapeutic targets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201849PMC
http://dx.doi.org/10.18632/oncotarget.26182DOI Listing

Publication Analysis

Top Keywords

exosomal survivin
8
survivin
5
tumor
5
exosomal
4
survivin facilitates
4
facilitates vesicle
4
vesicle internalization
4
internalization survivin
4
survivin member
4
member inhibitor
4

Similar Publications

Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes.

Drug Deliv Transl Res

January 2025

Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, 221005, Uttar Pradesh, India.

Cancer, particularly skin cancer, is a major cause of mortality worldwide, with melanoma being one of the most aggressive and challenging to treat types. Current therapeutic options, such as dacarbazine (DTIC), have limitations due to dose-related toxicities like liver toxicity. Therefore, there is a need for new and effective treatments for melanoma.

View Article and Find Full Text PDF

Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.

Stem Cell Res Ther

November 2024

Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang, 325027, China.

Article Synopsis
  • Cisplatin (DDP) is a common chemotherapy drug used for treating cervical cancer, particularly in advanced cases or for patients wishing to preserve fertility; TRAIL is a protein that can selectively induce death in cancer cells.
  • Human chorion-derived mesenchymal stem cells (hCD-MSCs) were modified to enhance TRAIL production and their exosomes (hCD-MSCs-Exo) were developed as delivery vehicles for DDP via a method called electroporation.
  • The combination of DDP and hCD-MSCs-Exo demonstrated improved effectiveness in reducing cancer cell proliferation and promoting apoptosis in vitro and in vivo, with minimal toxicity, indicating a promising therapeutic approach for cervical cancer treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Triple-negative breast cancer (TNBC) is a challenging type of breast cancer without specific treatment targets, primarily relying on traditional chemotherapy methods, making it essential to explore new therapeutic strategies.
  • Researchers engineered extracellular vesicles (EVs) using RNA nanotechnology to deliver targeted therapies specifically to TNBC cells by optimizing them with survivin small interfering RNA (siRNA) and CD44 aptamer ligands.
  • The study found that these engineered EVs dramatically reduced the required doses of chemotherapy drugs like gemcitabine and paclitaxel, showing effective tumor growth inhibition while potentially minimizing side effects associated with standard chemotherapy treatments.
View Article and Find Full Text PDF

Background: Neurogenic lower urinary tract dysfunction requires lifelong surveillance and management for the perseveration of patients' quality of life and the prevention of significant morbidity and mortality. Urine biomarkers are an attractive noninvasive method of surveillance for these patients. The aim of this systematic review is to search for and critically appraise studies that investigate the clinical usefulness of urine biomarkers in the management of neurogenic lower urinary tract dysfunction (NLUTD) in adults.

View Article and Find Full Text PDF

Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy.

Colloids Surf B Biointerfaces

January 2023

Department of School of Health Sciences & Technology, University of Petroleum and Energy Studies, Dehradun, India; Department of Chemical Engineering, University of Petroleum and Energy Studies, Dehradun, India. Electronic address:

Article Synopsis
  • Different therapeutic practices for cancer treatment have evolved beyond conventional methods, with nucleic acids therapy (NAT) and gene therapy gaining attention for their ability to inhibit tumors and prevent relapses by silencing oncogenic genes.
  • Effective delivery of exogenous nucleic acids, particularly short interfering RNAs (siRNAs), is crucial for NAT's success, with nano-based vehicles like liposomes, polymeric nanoparticles, and exosomes enhancing stability and preventing degradation.
  • Recent advancements in both targeted and non-targeted nanocarriers have improved the delivery of biological drugs to silence key genes linked to cancer progression and have been shown to positively impact therapeutic outcomes when combined with traditional chemotherapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!